• Patient Site
  • V-Go Customer Care
vgo green
  • Call 1-866-881-1209
  • Sign Up for Updates
  • About V-Go
    • What is V-Go®?
    • Who is it For?
    • How it Works
    • Why V-Go®?
  • Clinical Data
    • Efficacy
    • Insulin TDD
    • Patient Adherence
  • Prescribing & Dosing
    • Overview
  • Patient Support
    • Starting Patients
    • Comprehensive Support for You and Your Patients
    • Order Starter Kits & Resources
    • Common Patient Questions
  • Coverage & Savings
    • Overview
  • Pharmacists
    • Overview
    • Reimbursement Card

Insulin TDDV-Go® Reduces Daily Insulin Dose Requirements

V-Go: Proven Effective Regardless of Patient’s Insulin Dose

Patients prescribed ≥100 U/day (100 to 280 Units/day) saw significant A1c and insulin reductions4

clinical data chart

effect on glycemic control

View Baseline Characteristics

Methods: Electronic medical records were queried to identify patients switched from previous insulin therapy to insulin delivery with V-Go. 104 patients were stratified by moderate baseline insulin doses (<100 U/day) or high baseline insulin doses (≥100 U/day)(n=38) and compared using TDD U/day and U/kg. A1c and average prescribed insulin dosing were collected at baseline and for 2 follow-up A1c results on V-Go (the VALIDATE study). TDD=total daily dose.

References:  4. Lajara R, Nikkel C. Poster: Using V-Go wearable insulin delivery device in patients prescribed high insulin doses: a comparison of clinical results between high and moderate insulin dose groups. Presented at: the Diabetes Technology Meeting, Bethesda MD. October 2015.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.

  • Product Specs
  • Important Safety Information
  • Contact Us
  • Valeritas.com
  • Valeritas Newsroom
  • Terms of Use & Privacy
  • Cookies
  • Site Map
  • Twitter
  • YouTube
Valeritas logo
White V-Go® logo
© 2019 Valeritas Inc
Sign up for Updates About V-Go
Schedule a Live Demo
This website uses cookies to improve your browsing experience. Read MoreAccept